Skip to primary navigation Skip to main content
Buffalo Local Index
Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
Local Stocks
Beigene Ltd Ads (NQ: BGNE)
143.28 USD  UNCHANGED
Streaming Delayed Price  /  Updated: 4:08 PM EST, Jan 18, 2019  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 0
Open -
Bid (Size) 143.03 (1)
Ask (Size) 143.27 (1)
Prev. Close 143.28
Today's Range 143.28 - 143.28
52wk Range 105.19 - 220.10
Shares Outstanding 53,760,296
Dividend Yield N/A
Performance
YTD
+5.33%
+5.33%
1 Month
+16.91%
+16.91%
3 Month
+22.01%
+22.01%
6 Month
-18.11%
-18.11%
1 Year
+21.16%
+21.16%
Top News
More News
BeiGene Receives U.S. FDA Breakthrough Therapy Designation for Zanubrutinib in Mantle Cell Lymphoma
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the... Read More
from GlobeNewswire News Releases
BeiGene Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly targeted and immuno-oncology drugs for the... Read More
from GlobeNewswire News Releases
More News
Read More
BeiGene Initiates Two Global Phase 3 Front-Line Clinical Trials of Tislelizumab, in Patients with Gastric Cancer and in Patients with Esophageal Cancer
from GlobeNewswire News Releases
BeiGene Announces Updated Phase 1A/1B Data on Tislelizumab Presented at the European Society for Medical Oncology Immuno-Oncology Congress
from GlobeNewswire News Releases
BeiGene to Present Clinical Data on Anti-PD-1 Antibody Tislelizumab at the European Society for Medical Oncology Immuno-Oncology Congress
from GlobeNewswire News Releases
BeiGene Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
from GlobeNewswire News Releases
BeiGene Presents Clinical Results of Tislelizumab in Relapsed/Refractory Classical Hodgkin’s Lymphoma at the 60th American Society of Hematology Annual Meeting
from GlobeNewswire News Releases
Week In Review: Yantai's MabPlex Raises $59 Million To Expand CDMO Services
category Pharma/Biotech , Stocks / Equities
from Blogs - TalkMarkets
IEFA, CCEP, INXN, BGNE: ETF Inflow Alert
category ETFs
from ETF Channel
Stock Upgrades: Beigene Shows Rising Relative Strength
from Investor's Business Daily
Analysts Expect FNI To Hit $39
category ETFs
from ETF Channel
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.